Drug Sponsors

Enzymatics acquires ArcherDx and Next-Generation Diagnostic Technology

Friday, September 6, 2013 03:14 PM

Enzymatics, a producer of reagents, kits and assays, has acquired Boulder Colo.-based ArcherDx, a developer of NGS-based kits and software solutions for use in investigating cancer treatment. The deal consists of cash, equity and potential milestones worth up to $50 million.

More... »

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

More... »

ThromboGenics acquires exclusive rights from Bicycle Therapeutics

Friday, September 6, 2013 02:57 PM

ThromboGenics, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema (DME).

More... »

Mylan receives approval from India, acquires Agila

Wednesday, September 4, 2013 03:53 PM

Global pharmaceutical company Mylan’s proposed acquisition of the Agila injectables businesses from Indian pharmaceutical company Strides Arcolab has received approval from India's Foreign Investment Promotion Board (FIPB). The transaction also received approval from the Cabinet Committee on Economic Affairs (CCEA). The transaction is expected to close in the fourth quarter of 2013.

More... »

bioMérieux acquires BioFire Diagnostics

Wednesday, September 4, 2013 03:51 PM

bioMérieux, an in vitro diagnostics company, has acquired BioFire Diagnostics, a privately-held U.S.-based company specialized in molecular biology. BioFire invented, manufactures and commercializes its multiplex PCR FilmArray system, a simple and rapid molecular biology solution dedicated to the diagnosis of infectious diseases.

More... »

iPierian to launch True North Therapeutics

Wednesday, September 4, 2013 03:48 PM

iPierian, a biotechnology company developing novel therapies for neurodegenerative disease, has secured financing of $30 million  to continue to advance its drug development in neurodegenerative disease and  to launch a spin-out company, True North Therapeutics.

More... »

Elcelyx Therapeutics spins out NaZura BioHealth

Wednesday, September 4, 2013 03:47 PM

Elcelyx Therapeutics has established NaZura BioHealth, a separate company focusing on development of Gut Sensory Modulators (GSM) including lead product Lovidia, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet, the company’s proprietary delayed-release formulation of metformin for the treatment of patients with type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

More... »

GenVec board restructures operations, withdraws plan of dissolution

Wednesday, September 4, 2013 12:11 PM

The board of directors of GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has withdrawn the Plan of Complete Liquidation and Dissolution for the company, previously adopted May 24.

More... »

Neurotrope completes reverse merger

Wednesday, September 4, 2013 11:58 AM

Nevada-based Neurotrope (formerly BlueFlash Communications) has completed a reverse merger in which Neurotrope BioScience, based in Delaware, became a wholly owned subsidiary of the company.

More... »

Endo to acquire Boca Pharmacal

Friday, August 30, 2013 02:29 PM

Endo Health Solutions, a U.S.-based specialty healthcare company, will acquire privately-held Boca Pharmacal, a specialty generics company, for $225 million in cash. Boca Pharmacal focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.

More... »